Australia markets closed

AC Immune SA (IMR.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
2.7250+0.0850 (+3.22%)
As of 09:38AM CET. Market open.
Full screen
Previous close2.6400
Open2.6400
Bid2.7350 x 0
Ask2.9500 x 0
Day's range2.7050 - 2.7250
52-week range1.6000 - 4.5000
Volume565
Avg. volume1,243
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

    AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease on track for interim data in H2ACI-24.060 for Alzheimer’s disease (AD) received FDA Fast Track designationACI-35.030 ReTain Phase 2b program in preclinical (pre-symptomatic) AD patients, initiated by collaboration partnerCash of CHF 103 million at year end, plus the CHF 15 million

  • GlobeNewswire

    AC Immune Announces Upcoming Presentations at AD/PD™ 2024

    AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologies Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its preci

  • GlobeNewswire

    AC Immune to Regain Global Rights to Crenezumab and Semorinemab

    AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapiesActive immunotherapy now considered to be the optimal approach for precision prevention of neurodegenerative diseases Lausanne, Switzerland, January 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will re